Muscarinic acetylcholine receptors: New potential therapeutic targets in antinociception and in cancer therapy

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 2, 2008, Pages 93-103

  Tata, Ada Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Muscarinic receptors; Nociception; Tumours

Indexed keywords

3 (4 BUTYLTHIO 1,2,5 THIADIAZOL 3 YL)QUINUCLIDINE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINE; ALVAMELINE; CEVIMELINE; CMI 1145; CMI 936; DARIFENACIN; GALLAMINE; IPROTROPIUM; METHOCTRAMINE; MIGRASTATIN; MORPHINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR BLOCKING AGENT; MUSCARINIC M5 RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; OPIATE; OXITROPIUM BROMIDE; PIRENZEPINE; SOLIFENACIN; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDACLIDINE; XANOMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT;

ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINOCICEPTION; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CHOLINERGIC TRANSMISSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LOW DRUG DOSE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NUDE MOUSE; PAIN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; UROGENITAL TRACT DISEASE; ANIMAL; CHEMISTRY; METABOLISM; PHYSIOLOGY;

ACETYLCHOLINE; ANIMALS; CHOLINERGIC AGENTS; HUMANS; NEOPLASMS; PAIN; RECEPTORS, MUSCARINIC;

EID: 49149088469     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908784534621     Document Type: Review

References (96)

1. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The biological role of non neuronal acetylcholine in plants and humans. Jpn J Pharmacol 2001; 85: 2-10.
2. 2+ influx into embryonic cells after stimulation of the embryonic muscarinic receptors. J Dev Physiol 1992; 17: 147-155.
3. Buzanikov GA, Shumukler YB, Lauder JM. From oocytes to neuron: Do neurotransmitters function in the same way throughout development. Cell Mol Neurobiol 1996; 16: 533-559.
4. Grando SA, Pittelkow MR, Schellreunter KU. Adrenergic and cholinergic control in the biology of epidermis: Physiological and clinical Significance. J Invest Dermatol 2006; 126: 1948-1965.
5. Kawashima K, Fuji T. Expression of non neuronal acetylcholine in lymphocytes and its contributionof immune function. Front Biosci 2004; 9 (suppl): 2063-2085.
6. Proskocil BJ, Harmanjatinder SS, Yibing J, et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology 2004; 145: 2498-2506.
7. Whittacher VP. Identification of acetylcholine and related esters of biological origin. In Eichler O, Farah A, Koelle GB. Editors. Handbuch der Experimentellen Pharmakologie: B. Heidelberg, New York Springer 1963; 1-39.
8. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal cholinergic system in humans: Expression, function and pathophysiology. Life Sciences 2003; 72: 2055-2061.
9. Ma W, Li BS, Zhang L, Pant H. Signalling cascades implicated in muscarinic regulation of proliferation of neural stem and progenitor cells. Drug News Perspect 2004; 17: 258-266.
10. Zhou C, Wen ZX, Shi DM, Xie ZP. Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro. Cell Biol Inter 2004; 28: 63-67.
11. Augusti TG, Biagioni S, Tata AM. Acetylcholine and regulation of gene expression in developing systems. J Mol Neurosci 2006; 30: 45-47.
12. Loreti S, Ricordy R, Magnaghi V, Augusti TG, Tata AM. Acetylcholine controls the Schwann cell transition from proliferating to mature phenotype, counteracting the NRG1 action. International Proceedings: VIII European Meeting of the Glial Cells in Health and Disease. Medimomd Ed. 2007; 47-53.
13. Loreti S, Ricordy R, De Stefano ME, Augusti-Tocco G, Tata AM. Acetylcholine inhibits cell cycle progression in rat Schwann cells by activation of M2 receptor subtype. Neuron Glia Biology 2008; 3:1-11.
14. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-859.
15. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48.
16. De Simone R, Ajmone-Cat Ma, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2005; 25: 1-10.
17. Levey AI. Immunological localization of m1-m5 muscarinic receptor subtypesin peripheral tissues and brain. Life Sci 1993; 52: 441-448.
18. Ragheb F, Molina-Holgado E, Cui QL, et al. Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J Neurochem 2001; 77:1396-1406.
19. Loreti S, Vilarò MT, Visentin S, Rees H, Levey AI, Tata AM. Rat Schwann cells express M1-M4 muscarinic receptor subtypes. J Neurosci Res 2006; 84: 97-105.
20. Caufield MP, Birdsall NJM. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
21. Levine RR, Birdsall NJM. Subtypes of muscarinic receptors. Proceedings of the 4th international symposium on subtypes of muscarinic receptors. Trends Pharmacol Sci 1989; 10suppl: S1-s119.
22. Hulme EC, Birsall NJM, Buckley NJ. Muscarinic receptor subtypes. Ann Rev Pharmacol Toxicol 1990; 30:633-673.
23. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distint primary structures, ligand binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987; 6: 3923-3929.
24. Caufield MP. Muscarinic receptors: Characterization, coupling and function. Pharmacol Ther 1993; 58: 319-379.
25. Tence M, Cordier J, Premont J, Glowinski J. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture. J Pharmacol Exp Ther 1994; 269: 646-653.
26. Conklin BR, Brann MR, Buckley MJM, Banner IT, Axelrod J. Stimulation of arachidonic acid release and inhibitionof mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells. Proc Natl Acad Sci USA 1988; 85: 8698-8702.
27. Taylor P, Brown JH. Acetylcholine in basic neurochemistry. Siegel GJ, Agranoff BW, Albers RW, Molinoff PB. 1994. Raven Press.
28. Van Koppen CJ, Kaiser B. Regulation of muscarinic acetylcholine receptor signalling. Pharmacol Ther 2003; 98: 197-220.
29. Cui QL, Fogle E, Almazan G. Muscarinic acetylcholine receptors mediate survival through Src-like tyrosine kinase and PI3K/Akt pathways. Neurochem Int 2006; 48:383-393.
30. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. Nature Rev Drug Discovery 2007; 6: 721-733.
31. Stockton JM, Birdsall NJM, Burgen AS, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 44:102-110.
32. Ellis J, Seidenberg M, Brann MR. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1993; 42: 199-205.
33. Birdsall NJM, Farries T, Gharagozloo P, et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Science 1997; 60: 1047-1052.
34. Jerulinsky D, Cervenansky C, Pena C, Raskovsky S, Dajas F. Two polypeptides from Dendroaspis angusticeps venom selectivity inhibit the binding of central muscarinic cholinergic receptor ligands. Neurochem Int 1992; 20: 237-246.
35. Max SI, Liang JS, Potter LT. Purification and properties of m1-toxin, a specific antagonist of m1 muscarinic receptors. J Neurosci 1993; 13: 4293-4300.
36. Shannon HE, Sheardown MJ, Bymaster FP, et al. Pharmacology of butylthio [2.2.2] (LY297802/NNC11-1053): A novel analgesic with mixed muscarinic. receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-894.
37. Felder CC, Bymaster FP, Ward J, Delapp N. Therapeutic opportunities for muscarinic receptors in central nervous sytem. J Med Chem 2000; 43: 4333-4353.
38. Hedge SS, Mammen M, Jasper JR. Anti-muscarinic for the tratment of overactive bladder: Current options and emerging therapies. Curr Opin Inv Drugs 2004; 5:40-49.
39. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Autonomic and Autocoid Pharmacol 2005; 26: 219-233
40. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine: A new muscarinic receptor antagonist, is metabolized by cytochrome P4502D6 and 3A4 in human liver microsomes. Drug Metab Dispos 1998; 26: 289-293.
41. Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Europ J Pharmacol 2006; 529: 157-163.
42. Racke K, Juergens UR, Matthiesen S. Control by cholinergic mechanisms. Europ J Pharmacol 2006; 533: 57-68.
43. Racke K, Matthiesen S. The airway cholinergic system: Physiology and pharmacology. Pulm Pharmacol Ther 2004; 17: 181-198.
44. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Resp Med 2004; 3: 247-268.
45. Francis P, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzeihmer's disease: A review of progress. J Neurol Neurosurg Pychiatry 1999; 66: 137-147
46. Eglen RM, Choppin A, Dillon MP, Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Op Chem Biol 1999; 3: 426-432.
47. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1996; 93:13541-13546.
48. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in a Alzheimer disease. Arch Neurol 1997; 54: 465-473.
49. Fox RI. Sjogren'a syndrome: Evolving therapies. Expert Opin Invest Drugs 2003; 12: 247-254.
50. Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-M3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arth Rheum 2004; 50: 2615-2621.
51. Takeuchi, M., Naito, R., Hayakawa, M., Okamoto, Y., Yonetoku, Y., Ikeda, K., Isomura, Y.: US20006017927 (2000).
52. Meese, C., Sparf, B.: US2004186061 (2004).
53. Cross, P., Mackenzie, A.R.: US5096890 (1992).
54. Dolan, T.F., Humphrey, M.J., Nichols, D.J.: US20006106864 (2000).
55. Karl, Z., Werner, S., Rolf, B., Helmut, W.: US3505337 (1970).
56. Zeile, K., Banholzer, R., Walther, G., Schulz, W., Wick, H.: US3472861 (1969).
57. Box, P.C., Coe, D.M., Looker, B.E., Procopiou, P.A: US007271197B2 ( 2007).
58. Banholzer, R., Bauer, R., Reichl, R.: US5610163 (1997).
59. Joensson, N.A., Sparf, B.A., Mikiver, L., Moses, P., Nilvebrant, L., Glas, G.: US5382600 (1995).
60. Leonardi, A., Motta, G., Riva, C., Testa, R.: US006486163B1 (2001).
61. Kim, Y., Kang, S.B., Keum, G., Jang, M.S., Kong, J.Y., Jeong, D.Y.: US20030119880A1 (2002).
62. Bymaster, F.P., Horstmann, M., Shannon, H.E., Shipley, L.A., Valia, K.H.: US5980933 (1999).
63. Fisher, A., Karton, I., Heldman, E., Levy, A., Grunfeld, Y.: US4855290 (1989).
64. Hayashi, K., Tokumoto, S., Yoshizawa, H., Isogai, T., Kimura, M., Sawaki, M., Ando, T., Katsuyama, I., Ariyoshi, H., Nakamura, T.: US5571918 (1996).
65. Grewal, G., Toy-Palmer, A., Cai, X., Lathman, G.M.: US006323194B1 ( 2000).
66. Shannon HE, Sheardown JM, Bymaster FP, et al. Pharmacology of Butylthio [2.2.2](LY297802/NNC11-1053): A novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-894.
67. Sailer M, Oppitz M, Drews U. Induction of cellular contractions in the human melanoma cell line SK-mel 28 after muscarinic cholinergic stimulation. Anat Embryol 2000; 201: 27-37.
68. Oppitz M, Möbus V, Brock S, Drews U. Muscarinic receptors in cell lines from ovarian carcinoma: Negative correlation with survival of patients. Gynecologic Oncol 2002; 85: 159-164.
69. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, Shah GV. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. The prostate 1997; 30:160-166.
70. Frucht H, Jensen RT, Dexter D, Yang WI, Xiao Y. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clinical Cancer Res 1999; 5: 2532-2539.
71. Song P, Sekhon HS, Lu A, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007; 67: 3936-3944.
72. Guizzetti M, costa P, Peters J, Costa LG. Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Eur J Pharmacol 1996; 297: 265-273.
73. Boss A, Oppitz M, Drews U. Muscarinic cholinergic receptors in the human melanoma cell line SK-MEL28: Modulation of chemotaxis. Exp Dermatol 2005; 30: 557-564.
74. Rimmaudo LE, De la Torre H, Sacerdote de Lusting E, Sales ME. Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis. Biochem Bioph Res Comm 2005; 334: 1359-1364.
75. Jimenez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-686.
76. Tata AM, Augusti-Tocco G, Ferretti M, et al. Cholinergic control of gioblastoma cell line growth is mediated by different muscarinic receptor subtypes. Meeting of Italian Society of Neuroscience 2007. Abst sun05.
77. Song P, Sekhon HS, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63: 214-221.
78. Jimenez E, Montiel M. Activation of MAP kinase by Muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-686.
79. Guizzetti M, Wei M, Costa LG. The role of protein kinase C α and i̇sozymes in DNA synthesis induced by muscarinic receptors in a glial cell line. Eur J Pharmacol 1998; 359: 223-233.
80. Bordey A, Sontheimer H, Thouslard J. Muscarinic activation of BK channels induces membrane oscillations in glioma cells and leads to inhibition of cell migration. J Membrane Biol 2000; 176: 31-40.
81. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmakinet 2006; 45: 325-350.
82. Nakae K, Nishimura Y, Ohba S, Akamatsu Y. Migrastatin acts as a muscarinic acetylcholine receptor antagonist. J Antibiot 2006; 59: 685-692.
83. Bernardini N, Levey AI, Augusti TG. Rat dorsal root ganglia express m1-m4 muscarinic receptor proteins. J Pheripheral Nervous System 1999; 4: 222-232.
84. Tata AM, Vilaró MT, Mengod G. Muscarinic receptor subtypes expression in rat and chick dorsal root ganglia. Mol Brain Res 2000; 82: 1-10.
85. Iwamoto ET, Marion L. Characterization of the antinociception produced by intrathecally administered muscarinic agonistsin rats. J Pharmacol Exp Ther 1993; 266: 329-338.
86. Widman M, Tucker S, Brase DA, Dewey WL. Cholinergic agents: antinociception without morphine type dependence in rats. Life Sci 1985; 36: 2007-2015.
87. Wess J, Duttaroy A, Gomeza J, et al. Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: A review. Life Sciences 2003; 72: 2047-2054.
88. Honda K, Harada A, Takano Y, Kamira H. Involvement of M3 muscarinic receptors of the spinal cord in formalin-induced nociception in mice. Brain Res 2000; 859: 38-44.
89. Bernardini N, Sauer S, Haberberger R, Fisher MJM, Reeh PW. Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin. J Neurosci 2001; 21: 3295-3302.
90. Bernardini N, Roza C, Sauer S, Gomeza J, Wess J, Reeh W. Muscarinic M2 receptors on peripheral nerve endings: A molecular target of antinociception. J Neurosci 2002; 22: 1-5.
91. Dussor GO, Helesic G, Hargreaves KM, Flores CM. Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron. Pain 2004; 107: 22-32.
92. Ellis JL, Harman D, Gonzalez J, et al. Development of muscarinic analgesic derived from epibatidine: Role of the M4 receptor subtype. J Pharmacol Exper Ther 1999; 288: 1143-1150.
93. Wess J. Muscarinic acetylcholine receptor knockout mice: Novel phenotypes and clinical implications. Ann Rev Pharmacol Toxicol 2004; 44: 423-450.
94. Wang HNG, Hayes D, Gao X, Forster G, Blaha C, Yeomans J. Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. Neurospycopharmacology 2005; 29: 2126-2139.
95. Mammen, M., Yu-Hua, J., Dunham, S., Li, L.: US2007151115B2 (2006).
96. Drutu, I., Hurley, D.J., Bandarage, U.P., Bergeron, D.J., Charifson, P.S., Davies, R.J., Blanco, G.G., Makings, L.R., Nakatani, A., Raffai, G.: US20060270653A1 (2007).